Systemic lupus erythematosus and lupus nephritis (original) (raw)

• From the Analyst's Couch
• Published: 14 February 2014

Nature Reviews Drug Discovery volume 13, pages 173–174 (2014)Cite this article

• 9282 Accesses
• 66 Citations
• 10 Altmetric
• Metrics details

Subjects

The clinical course of SLE can vary from mild symptoms to life-threatening multi-organ disease. We estimate that there were approximately 0.45 million diagnosed cases of SLE in 2012 in the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan), a number that is expected to grow steadily to 0.48 million by 2022 owing to increases in the population and life expectancy, and improvements in disease awareness and diagnosis1.

Current therapies

References

1. Koutsokeras, T. & Healy, T. PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis — Global Drug Forecast and Market Analysis to 2022 (GlobalData, 2013).
   Google Scholar
2. Lateef, A. & Petri, M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res. Ther. 14, S4 (2012).
   Article Google Scholar

Download references

Author information

Authors and Affiliations

1. GlobalData, 40–42 Hatton Garden, London, EC1N 8EB, UK
   Toli Koutsokeras
2. GlobalData, 40–42 Hatton Garden, London, EC1N 8EB, UK
   Tina Healy

Authors

1. Toli Koutsokeras
2. Tina Healy

Corresponding authors

Correspondence toToli Koutsokeras or Tina Healy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

About this article

Cite this article

Koutsokeras, T., Healy, T. Systemic lupus erythematosus and lupus nephritis.Nat Rev Drug Discov 13, 173–174 (2014). https://doi.org/10.1038/nrd4227

Download citation

• Published: 14 February 2014
• Issue date: March 2014
• DOI: https://doi.org/10.1038/nrd4227

This article is cited by